Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 8, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Reiterated (TRVI) at Strong Buy and Held Target at $8 on, May 8th, 2024
Serge Belanger of Needham, Reiterated "Trevi Therapeutics, Inc." (TRVI) at Strong Buy and Held Target at $8 on, May 8th, 2024.
Serge has made no other calls on TRVI in the last 4 months.
There is 1 other peer that has a rating on TRVI. Out of the 1 peers that are also analyzing TRVI, 0 agree with Serge's Rating of Hold.
This is the rating of the analyst that currently disagrees with Serge
- Leland Gershell of "Oppenheimer" Maintained at Buy and Held Target at $9 on, Thursday, March 21st, 2024
